Abstract
Although randomized trials have proven the benefit of carotid endarterectomy (CEA) for appropriate patients, health care purchasers increasingly look beyond clinical outcome toward measures of cost effectiveness and health-related quality of life (HRQoL) in apportioning limited resources. We used a generic HRQoL outcome scale, the Short Form 36 (SF-36), to assess the differences in patient-perceived HRQoL in two cohorts of patients who had suffered minor cerebral ischemic events. One group (n=100) had undergone CEA, whereas members of the second cohort (n=100) were not appropriate candidates for surgery and were therefore treated with best medical therapy. The overall response rate was 83%. No significant difference in health profile between the CEA and medical cohorts was detected for the eight SF-36 domains. However, the CEA cohort rated a significantly improved change in general health over the previous year compared with the group managed medically (P<.01). A greater proportion of the former group than of the medical group thought their treatment had been successful and that their health had been improved by treatment (P<.01). Both groups shared the same anxieties over future cerebral ischemic events (P=.3). Patients' perception of HRQoL measured by the SF-36 domains was almost identical between the CEA and medical cohorts apart from a small but significant improvement in self-reported overall health in the CEA cohort. HRQoL outcome measures may be of value in future clinical trials of cerebral revascularization.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have